SK7162002A3 - 2-arylquinoline derivatives, preparation and therapeutic use thereof - Google Patents

2-arylquinoline derivatives, preparation and therapeutic use thereof Download PDF

Info

Publication number: SK7162002A3
Authority: SK; Slovakia
Prior art keywords: group; carbon atoms; alkyl; phenyl; formula
Prior art date: 1999-11-25

Application number

SK716-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Philippe R Bovy

Alain Braun

Christophe Philippo

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-25

Filing date

2000-11-21

Publication date

2002-11-06

2000-11-21 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2002-11-06 Publication of SK7162002A3 publication Critical patent/SK7162002A3/sk

Links

238000002360 preparation method Methods 0.000 title claims description 8
230000001225 therapeutic effect Effects 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 101
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 48
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 37
125000000217 alkyl group Chemical group 0.000 claims abstract description 23
-1 perfluoro Chemical group 0.000 claims abstract description 22
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 15
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
229910052736 halogen Inorganic materials 0.000 claims abstract description 12
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 11
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 11
125000001624 naphthyl group Chemical group 0.000 claims abstract description 11
150000002367 halogens Chemical class 0.000 claims abstract description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
125000002947 alkylene group Chemical group 0.000 claims abstract description 5
125000003396 thiol group Chemical class [H]S* 0.000 claims abstract description 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 3
125000004450 alkenylene group Chemical group 0.000 claims abstract description 3
125000004414 alkyl thio group Chemical group 0.000 claims abstract description 3
125000004043 oxo group Chemical group O=* 0.000 claims abstract description 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 31
238000000034 method Methods 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
125000005843 halogen group Chemical group 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 9
150000001412 amines Chemical class 0.000 claims description 8
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
125000005936 piperidyl group Chemical group 0.000 claims description 8
125000006239 protecting group Chemical group 0.000 claims description 8
125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
IAUWIWVZCQXEFK-UHFFFAOYSA-N 2-(diethylamino)-2-(2-phenylquinolin-8-yl)ethanol Chemical compound N1=C2C(C(CO)N(CC)CC)=CC=CC2=CC=C1C1=CC=CC=C1 IAUWIWVZCQXEFK-UHFFFAOYSA-N 0.000 claims description 6
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
125000002393 azetidinyl group Chemical group 0.000 claims description 3
125000004663 dialkyl amino group Chemical group 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
201000002282 venous insufficiency Diseases 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 2
BSYCYJOKKPWUOU-UHFFFAOYSA-N 2-(diethylamino)-2-(2-thiophen-2-ylquinolin-8-yl)ethanol Chemical compound N1=C2C(C(CO)N(CC)CC)=CC=CC2=CC=C1C1=CC=CS1 BSYCYJOKKPWUOU-UHFFFAOYSA-N 0.000 claims description 2
IUUUPXZWLMLJLO-UHFFFAOYSA-N 2-(diethylamino)-2-(3-methyl-2-phenylquinolin-8-yl)ethanol Chemical compound N1=C2C(C(CO)N(CC)CC)=CC=CC2=CC(C)=C1C1=CC=CC=C1 IUUUPXZWLMLJLO-UHFFFAOYSA-N 0.000 claims description 2
208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
208000019695 Migraine disease Diseases 0.000 claims description 2
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
125000003709 fluoroalkyl group Chemical group 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
DVQWRTAYBSDNHK-UHFFFAOYSA-N 2-(diethylamino)-2-[2-(2-fluorophenyl)-3-methylquinolin-8-yl]ethanol Chemical compound N1=C2C(C(CO)N(CC)CC)=CC=CC2=CC(C)=C1C1=CC=CC=C1F DVQWRTAYBSDNHK-UHFFFAOYSA-N 0.000 claims 1
206010046543 Urinary incontinence Diseases 0.000 claims 1
125000003282 alkyl amino group Chemical group 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 5
125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
239000003921 oil Substances 0.000 description 46
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
239000000203 mixture Substances 0.000 description 39
239000000243 solution Substances 0.000 description 31
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
239000011541 reaction mixture Substances 0.000 description 23
239000012074 organic phase Substances 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
229910052943 magnesium sulfate Inorganic materials 0.000 description 21
235000019341 magnesium sulphate Nutrition 0.000 description 21
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
238000010898 silica gel chromatography Methods 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 14
239000002904 solvent Substances 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 10
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000008346 aqueous phase Substances 0.000 description 8
125000001309 chloro group Chemical group Cl* 0.000 description 7
239000012230 colorless oil Substances 0.000 description 7
239000012153 distilled water Substances 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
OIFKDCSXVOPKJS-UHFFFAOYSA-N (3-methyl-2-phenylquinolin-8-yl) trifluoromethanesulfonate Chemical compound CC1=CC2=CC=CC(OS(=O)(=O)C(F)(F)F)=C2N=C1C1=CC=CC=C1 OIFKDCSXVOPKJS-UHFFFAOYSA-N 0.000 description 6
UKXHIBKTXAQYTP-UHFFFAOYSA-N 3-methyl-2-phenylquinolin-8-ol Chemical compound CC1=CC2=CC=CC(O)=C2N=C1C1=CC=CC=C1 UKXHIBKTXAQYTP-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
230000000694 effects Effects 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
230000004044 response Effects 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
UUYSPVQFUCOKFE-UHFFFAOYSA-N 8-methoxy-3-methyl-2-phenylquinoline Chemical compound N1=C2C(OC)=CC=CC2=CC(C)=C1C1=CC=CC=C1 UUYSPVQFUCOKFE-UHFFFAOYSA-N 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
238000009835 boiling Methods 0.000 description 5
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
OWJDLKGVHMTXSG-UHFFFAOYSA-N 8-ethenyl-1h-quinolin-2-one Chemical compound C1=CC=C(C=C)C2=NC(O)=CC=C21 OWJDLKGVHMTXSG-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
150000003248 quinolines Chemical class 0.000 description 4
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
BQMKWGDPMAXHMC-OAQYLSRUSA-N (1s)-2-[tert-butyl(dimethyl)silyl]oxy-1-(3-methyl-2-phenylquinolin-8-yl)ethanol Chemical compound CC1=CC2=CC=CC([C@H](O)CO[Si](C)(C)C(C)(C)C)=C2N=C1C1=CC=CC=C1 BQMKWGDPMAXHMC-OAQYLSRUSA-N 0.000 description 3
NJCGWIGYDBJZQL-UHFFFAOYSA-N (8-ethenylquinolin-2-yl) acetate Chemical compound C1=CC=C(C=C)C2=NC(OC(=O)C)=CC=C21 NJCGWIGYDBJZQL-UHFFFAOYSA-N 0.000 description 3
INAJRDUYUDXAJJ-UHFFFAOYSA-N (8-ethenylquinolin-2-yl) trifluoromethanesulfonate Chemical compound C1=CC=C(C=C)C2=NC(OS(=O)(=O)C(F)(F)F)=CC=C21 INAJRDUYUDXAJJ-UHFFFAOYSA-N 0.000 description 3
LNIRACBTZBHVMZ-UHFFFAOYSA-N (8-hydroxyquinolin-2-yl) acetate Chemical compound C1=CC=C(O)C2=NC(OC(=O)C)=CC=C21 LNIRACBTZBHVMZ-UHFFFAOYSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
GDIYDPBHVKDDIR-UHFFFAOYSA-N 2-amino-3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1N GDIYDPBHVKDDIR-UHFFFAOYSA-N 0.000 description 3
GHDFRXJIHVVVNQ-UHFFFAOYSA-N 8-ethenyl-3-methyl-2-phenylquinoline Chemical compound CC1=CC2=CC=CC(C=C)=C2N=C1C1=CC=CC=C1 GHDFRXJIHVVVNQ-UHFFFAOYSA-N 0.000 description 3
FJKUOCCQEBLPNX-UHFFFAOYSA-N 8-hydroxyquinoline N-oxide Chemical compound C1=C[N+]([O-])=C2C(O)=CC=CC2=C1 FJKUOCCQEBLPNX-UHFFFAOYSA-N 0.000 description 3
HKEAUNIJRGMLRM-UHFFFAOYSA-N 8-methoxy-3-methylquinoline Chemical compound CC1=CN=C2C(OC)=CC=CC2=C1 HKEAUNIJRGMLRM-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
QUMSKYDPCVXOHI-UHFFFAOYSA-N [8-(1,2-dihydroxyethyl)quinolin-2-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)N=C2C(C(O)CO)=CC=CC2=C1 QUMSKYDPCVXOHI-UHFFFAOYSA-N 0.000 description 3
AIIDPCMTBMXAQR-UHFFFAOYSA-N [8-(trifluoromethylsulfonyloxy)quinolin-2-yl] acetate Chemical compound C1=CC=C(OS(=O)(=O)C(F)(F)F)C2=NC(OC(=O)C)=CC=C21 AIIDPCMTBMXAQR-UHFFFAOYSA-N 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
230000037020 contractile activity Effects 0.000 description 3
238000001816 cooling Methods 0.000 description 3
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000000269 nucleophilic effect Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
210000003708 urethra Anatomy 0.000 description 3
YUCBLVFHJWOYDN-PPIALRKJSA-N 4-[(r)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]-1-[(r)-[(2r,4r,5s)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C4=CC=CC=C4C(O[C@@H]([C@@H]4N5CC[C@@H]([C@@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-PPIALRKJSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
MOFLSTWEGYWIBB-JOCHJYFZSA-N [(1s)-2-[tert-butyl(dimethyl)silyl]oxy-1-(3-methyl-2-phenylquinolin-8-yl)ethyl] methanesulfonate Chemical compound CC1=CC2=CC=CC([C@@H](CO[Si](C)(C)C(C)(C)C)OS(C)(=O)=O)=C2N=C1C1=CC=CC=C1 MOFLSTWEGYWIBB-JOCHJYFZSA-N 0.000 description 2
LBECLEDYQKPXFJ-UHFFFAOYSA-N [8-[2-[tert-butyl(dimethyl)silyl]oxy-1-(diethylamino)ethyl]quinolin-2-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)N=C2C(C(CO[Si](C)(C)C(C)(C)C)N(CC)CC)=CC=CC2=C1 LBECLEDYQKPXFJ-UHFFFAOYSA-N 0.000 description 2
RUDQRFAVSMZTIA-UHFFFAOYSA-N [8-[2-[tert-butyl(dimethyl)silyl]oxy-1-hydroxyethyl]quinolin-2-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)N=C2C(C(O)CO[Si](C)(C)C(C)(C)C)=CC=CC2=C1 RUDQRFAVSMZTIA-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000001595 contractor effect Effects 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
238000005906 dihydroxylation reaction Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000012453 solvate Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
VPDAGUVEZGEHJJ-UHFFFAOYSA-N 2-quinolin-2-ylethanol Chemical compound C1=CC=CC2=NC(CCO)=CC=C21 VPDAGUVEZGEHJJ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
GDTUACILWWLIJF-UHFFFAOYSA-N 3-methoxy-2-nitrobenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1[N+]([O-])=O GDTUACILWWLIJF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
239000005725 8-Hydroxyquinoline Substances 0.000 description 1
HLQHZIHJEJRDOX-UHFFFAOYSA-N 8-methoxy-2-methyl-2-phenyl-1h-quinoline Chemical compound N1C=2C(OC)=CC=CC=2C=CC1(C)C1=CC=CC=C1 HLQHZIHJEJRDOX-UHFFFAOYSA-N 0.000 description 1
102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
241000220479 Acacia Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000006890 Doebner-Miller synthesis reaction Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000005614 Skraup synthesis reaction Methods 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000000558 Varicose Ulcer Diseases 0.000 description 1
OHZZCIZHWVFLMK-UHFFFAOYSA-N [8-[1-(diethylamino)-2-hydroxyethyl]quinolin-2-yl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)N=C2C(C(CO)N(CC)CC)=CC=CC2=C1 OHZZCIZHWVFLMK-UHFFFAOYSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000006204 intramuscular dosage form Substances 0.000 description 1
239000006207 intravenous dosage form Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
210000003975 mesenteric artery Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
244000309715 mini pig Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000007344 nucleophilic reaction Methods 0.000 description 1
VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002900 organolithium compounds Chemical class 0.000 description 1
150000002901 organomagnesium compounds Chemical class 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229960003540 oxyquinoline Drugs 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000009101 premedication Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000006203 subcutaneous dosage form Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D333/10—Thiophene
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SK716-2002A 1999-11-25 2000-11-21 2-arylquinoline derivatives, preparation and therapeutic use thereof SK7162002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9914817A FR2801589A1 (fr)	1999-11-25	1999-11-25	Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique
PCT/FR2000/003224 WO2001038310A1 (fr)	1999-11-25	2000-11-21	Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
SK7162002A3 true SK7162002A3 (en)	2002-11-06

Family

ID=9552515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK716-2002A SK7162002A3 (en)	1999-11-25	2000-11-21	2-arylquinoline derivatives, preparation and therapeutic use thereof

Country Status (24)

Country	Link
US (1)	US6617336B1 (is)
EP (1)	EP1240146A1 (is)
JP (1)	JP2003526633A (is)
KR (1)	KR20020058036A (is)
CN (1)	CN1413196A (is)
AU (1)	AU2521501A (is)
BG (1)	BG106737A (is)
BR (1)	BR0015787A (is)
CA (1)	CA2392149A1 (is)
CZ (1)	CZ20021786A3 (is)
EA (1)	EA200200462A1 (is)
EE (1)	EE200200266A (is)
FR (1)	FR2801589A1 (is)
HR (1)	HRP20020455A2 (is)
HU (1)	HUP0203455A3 (is)
IL (1)	IL149653A0 (is)
IS (1)	IS6391A (is)
MX (1)	MXPA02005019A (is)
NO (1)	NO20022482L (is)
PL (1)	PL356159A1 (is)
SK (1)	SK7162002A3 (is)
TR (1)	TR200201352T2 (is)
WO (1)	WO2001038310A1 (is)
ZA (1)	ZA200204064B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5147204B2 (ja) *	2006-07-27	2013-02-20	大塚製薬株式会社	カルボスチリル誘導体の製造方法
AR062156A1 (es) *	2006-08-01	2008-10-22	Praecis Pharm Inc	Compuestos agonistas y selectivos del receptor s1p-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2731708B1 (fr) *	1995-03-13	1997-04-30	Synthelabo	Derives de piperidine, leur procede de preparation et leur application en therapeutique
EP0888324A1 (fr)	1996-03-08	1999-01-07	Synthelabo	Derives de 2-aminoethyl-benzofurane, leur preparation et leur application en therapeutique
FR2752840A1 (fr) *	1996-08-29	1998-03-06	Synthelabo	Derives de benzothiophene, leur preparation et leur application en therapeutique
FR2752839B1 (fr)	1996-08-29	1998-10-09	Synthelabo	Derives de benzofurane, leur preparation et leur application en therapeutique
FR2756564B1 (fr) *	1996-12-04	2004-05-14	Synthelabo	Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
FR2783247B1 (fr) *	1998-09-10	2000-11-17	Synthelabo	Derives de 2-aminoethyl-quinoleine, leur preparation et leur application en therapeutique
FR2785903B1 (fr) *	1998-11-17	2002-10-25	Synthelabo	Derives de 1-aminoethylquinoleine, leur preparation et leur application en therapeutique

1999
- 1999-11-25 FR FR9914817A patent/FR2801589A1/fr not_active Withdrawn
2000
- 2000-11-21 BR BR0015787-2A patent/BR0015787A/pt not_active Application Discontinuation
- 2000-11-21 HR HR20020455A patent/HRP20020455A2/hr not_active Application Discontinuation
- 2000-11-21 KR KR1020027006647A patent/KR20020058036A/ko not_active Withdrawn
- 2000-11-21 MX MXPA02005019A patent/MXPA02005019A/es unknown
- 2000-11-21 AU AU25215/01A patent/AU2521501A/en not_active Abandoned
- 2000-11-21 CZ CZ20021786A patent/CZ20021786A3/cs unknown
- 2000-11-21 PL PL00356159A patent/PL356159A1/xx not_active Application Discontinuation
- 2000-11-21 IL IL14965300A patent/IL149653A0/xx unknown
- 2000-11-21 EE EEP200200266A patent/EE200200266A/xx unknown
- 2000-11-21 JP JP2001540073A patent/JP2003526633A/ja not_active Withdrawn
- 2000-11-21 EA EA200200462A patent/EA200200462A1/ru unknown
- 2000-11-21 TR TR2002/01352T patent/TR200201352T2/xx unknown
- 2000-11-21 CN CN00817802A patent/CN1413196A/zh active Pending
- 2000-11-21 SK SK716-2002A patent/SK7162002A3/sk unknown
- 2000-11-21 CA CA002392149A patent/CA2392149A1/en not_active Abandoned
- 2000-11-21 HU HU0203455A patent/HUP0203455A3/hu unknown
- 2000-11-21 US US10/130,875 patent/US6617336B1/en not_active Expired - Fee Related
- 2000-11-21 EP EP00988858A patent/EP1240146A1/fr not_active Withdrawn
- 2000-11-21 WO PCT/FR2000/003224 patent/WO2001038310A1/fr not_active Ceased
2002
- 2002-05-21 IS IS6391A patent/IS6391A/is unknown
- 2002-05-22 ZA ZA200204064A patent/ZA200204064B/en unknown
- 2002-05-22 BG BG106737A patent/BG106737A/bg unknown
- 2002-05-24 NO NO20022482A patent/NO20022482L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2001038310A1 (fr)	2001-05-31
JP2003526633A (ja)	2003-09-09
BG106737A (bg)	2003-04-30
EP1240146A1 (fr)	2002-09-18
CZ20021786A3 (cs)	2002-08-14
NO20022482D0 (no)	2002-05-24
US6617336B1 (en)	2003-09-09
ZA200204064B (en)	2003-07-30
HUP0203455A3 (en)	2003-12-29
IS6391A (is)	2002-05-21
AU2521501A (en)	2001-06-04
PL356159A1 (en)	2004-06-14
CN1413196A (zh)	2003-04-23
CA2392149A1 (en)	2001-05-31
MXPA02005019A (es)	2003-01-28
IL149653A0 (en)	2002-11-10
EA200200462A1 (ru)	2002-10-31
FR2801589A1 (fr)	2001-06-01
HUP0203455A2 (hu)	2003-02-28
BR0015787A (pt)	2002-08-13
HRP20020455A2 (en)	2003-08-31
TR200201352T2 (tr)	2003-02-21
EE200200266A (et)	2003-06-16
NO20022482L (no)	2002-07-24
KR20020058036A (ko)	2002-07-12

Publication	Publication Date	Title
CA2065644C (en)	2002-12-03	Pyrazolopyridine compound and processes for preparation thereof
FR2823209A1 (fr)	2002-10-11	Nouvelles thiohydantoines et leur utilisation en therapeutique
CS247073B2 (en)	1986-11-13	Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins
FI67686C (fi)	1985-05-10	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
EP0539153B1 (en)	1997-04-23	Acridine derivative as therapeutic agent
WO2019101171A1 (zh)	2019-05-31	噻吩并环类化合物及其合成方法和应用
JP3853389B2 (ja)	2006-12-06	新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、その製法及び抗不整脈剤
JPH0358987A (ja)	1991-03-14	新規化合物、その製法及びそれを含む医薬組成物
US20030097000A1 (en)	2003-05-22	2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof
US6331549B1 (en)	2001-12-18	1-aminoethylquinoline derivatives for treating urinary incontinence
FI115630B (fi)	2005-06-15	Menetelmä 4-(3-syaanifenyyli)-trifluorimetyyli-5-okso-1,4,5,6,7,8-heksahydrokinoliini-3-karboksyylihapon valmistamiseksi
CZ20021786A3 (cs)	2002-08-14	Deriváty 2-arylchinolinu, způsob jejich přípravy a farmaceutické kompozice, které je obsahují
KR102640385B1 (ko)	2024-02-23	고혈압 및/또는 폐 섬유증 치료용 조성물
US8383631B2 (en)	2013-02-26	1,6-disubstituted-3-amino-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-C]pyridin-7-one compounds and preparation thereof
JP2002511451A (ja)	2002-04-16	アザシクロアルカン誘導体、その製造及び治療上の使用
JPH0853457A (ja)	1996-02-27	５，６−ジヒドロ−４Ｈ−チエノ［３，４−ｃ］ピロール誘導体、それらの製造およびそれらの治療薬としての利用
KR100503518B1 (ko)	2005-07-25	2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법
JP2001048865A (ja)	2001-02-20	経鼻剤
CN121824350A (zh)	2026-04-10	取代丙酸衍生物及其用途
JPH0459776A (ja)	1992-02-26	フェノキシプロピルアミン誘導体およびこれを含有する抗潰瘍剤
KR890004662B1 (ko)	1989-11-24	1,8-나프티리딘과 1,5,8-아자나프티리딘 유도체 및 이의 제조방법
EP0633026A1 (en)	1995-01-11	Use of imidazole derivative for antihypertensive agent
JP2005519084A (ja)	2005-06-30	（２’ｓ，３ｓ）−３−ヒドロキシ−ｎ−｛２−［ｎ−メチル−ｎ−４−（ｎ−プロピルアミノ−カルボニル）フェニル］アミノ−２−フェニル｝−エチルピロリジンの結晶性で無水の一水和物安息香酸塩
JPH0920664A (ja)	1997-01-21	麻薬拮抗剤
HK1054936A (en)	2003-12-19	2-arylquinoline derivatives, preparation and therapeutic use thereof